Name: Ning Qin

Professor in Tongji Hospital

Phone: 86-27-83662391

Email: qning@

Academic Areas: Department of Infectious Disease;Institute of Infectious Diseases

Research Interest

Dr. Ning’s clinical care activities include infectious disease, clinical immunology, and hepatology with focus on hepatitis


Ph.D.--Molecular Microbiology and Immunology, Infectious Disease--TongJi Medical University,Wuhan,China--1993

M.Sc.--Molecular Microbiology and Immunology, Infectious Disease--Tongji Medical University, Wuhan,China--1990

MD--Clinic Medicine-- Tongji Medical University,Wuhan,China--1985

Oversea Study and Visit

Post Doctoral,Toronto General Hospital and the University of Toronto,,Canada,1994-02-03-2000-10-03

Academic Memberships

President , Hubei Provincial Society for Infectious Disease, Hubei Provincial Medical Society ,2013-05-31.2017-05-31

A Standing Committee ,Chinese Society of Infectious Disease,Chinese Medical Society ,2013-12-03.2017-12-03

Honours and Awards

Natural Science Award,Hubei Provincial Government ,2011

Honours and Awards

[1] Han M, Yan W, Guo W, Xi D, Zhou Y, Li W, Gao S, Liu M, Levy G, Luo X, Ning Q(corresponding author)., Hepatitis B virus induced HFGl2 transcription is dependent on c-Ets-2 and MAPK signal pathway., J Biol Chem.,2008, 2008.283(11):32715-32729.

[2] Zou Y, Chen T, Meifang Han, Wang H, Yan W, Song G, Wu Z, Wang X, Zhu C, Luo X, Qin Ning(corresponding author). ,Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. ,The Journal of Immunology.,2010,2010,184(1):466-475.

[3] Sui Gao, Ming Wang, Huali Ye, Jianwen Guo, Dong Xi, Zhimo Wang, Chuanglong Zhu, Weiming Yan, Xiaoping Luo, Qin Ning(corresponding author). ,Dual interference of novel gene mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice., Human Gene Therapy.,2010,2010, 21(8): 969-977.

[4] Zeguang Wu, Meifang Han, Tao Chen, Weiming Yan, Qin Ning. (corresponding author)., Acute Liver Failure: Mechanisms of Immune-Mediated Liver Injury. ,Liver International,,2010, 2010, 30(6):782-794.

[5]  Yanling Liu, Li Xu, Qili Zeng, Jingli Wang, Ming Wang, Dong Xi, Xiaojing Wang, Daofeng Yang, Xiaoping Luo, and Qin Ning* (corresponding author). ,Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis., Liver International,2012,2012, 32(10):1585-1595.

[6]  Tao Chen, Lin Zhu, Yaoyong Zhou, Bin Pi, Xiaojuan Liu, Guohong Deng, Rong Zhang, Yuming Wang, Zeguang Wu, Meifang Han, Xiaoping Luo, Qin Ning* (corresponding author). ,KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure. ,Clinical Immunology. ,2013,2013, 146(3):207-216.

[7] Dong Xi, Ming Wang, Huali Ye, Xiaoping Luo, Qin Ning* (corresponding author).Combined adenovirus-mediated artificial microRNAs targeting mfgl2 mFas and mTNFR1 protect against fulminant hepatic failure in mice., PLOS ONE.,2013, 8(11): e82330, 1-12.

[8] Qin Ning (corresponding author), Meifang Han, Yongtao Sun, Jiaji Jiang, Deming Tan, Jinlin Hou, Hong Tang, Jifang Sheng, Mianzhi Zhao. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized open-label trial (OSST trial),Journal of Hepatology 2014, Oct;61(4):777-784

[9] Li L, Wu T, Huang J, Ma K, Xu L, Wang H, Fan X, Tao R, Ai G, Ning Q.Expression of heat shock protein 47, transforming growth factor-beta 1, and connective tissue growth factor in liver tissue of patients with Schistosoma japonicum-induced hepatic fibrosis. Parasitology. 2014 Aug 11:1-11.(E PUB)

[10] Ying Sun, Dong Xi, Wen Ding, Faxi Wang,Haili Zhou, Qin Ning(corresponding author). Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma. Hepatology International. 2014, 25;8(4):567-575

[11] Di Wu, Meifang Han, Qin Ning(corresponding author). An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: the future of chronic hepatitis B? Journal of Hepatology, 2014(Accepted)